Membrane polyunsaturated fatty acids (PUFAs)

Membrane polyunsaturated fatty acids (PUFAs) are critical structural and functional components of cellular and organelle membranes, particularly enriched in the central nervous system and retina (NIH, 2012). These fatty acid chains, typically found at the sn-2 position of phospholipids, are essential for maintaining membrane fluidity, elasticity, and the optimal function of embedded proteins such as G protein-coupled receptors and ion channels (PNAS, 2007). However, the presence of bis-allylic hydrogens makes these chains highly susceptible to non-enzymatic lipid peroxidation, a process that drives ferroptosis, an iron-dependent form of regulated cell death (Cell, 2012). This oxidative degradation is implicated in the pathogenesis of various neurodegenerative conditions, including Friedreich's ataxia and amyotrophic lateral sclerosis (Retrotope, 2022). Therapeutic interventions target these chains either to prevent their oxidation—such as through the use of deuterated PUFAs like RT001 which utilize the kinetic isotope effect—or to promote peroxidation in the context of cancer therapy (Nature Chemical Biology, 2016). By stabilizing or modifying the composition of these lipid chains, drugs can protect cell viability or modulate signaling pathways associated with membrane-lipid therapy (Laminar Pharmaceuticals, 2024).

Other names

Lipid bilayer polyunsaturated fatty acid chainsMembrane PUFAsPolyunsaturated fatty acid-containing phospholipidssn-2 polyunsaturated fatty acid chainsMembrane polyunsaturated lipids

Drugs targeting these molecules primarily act by inhibiting lipid peroxidation through radical scavenging or by reinforcing the fatty acid chains against oxidative attack using the kinetic isotope effect (Retrotope, 2022; Cell, 2012). Additionally, some therapies involve the direct incorporation of specific PUFAs or their derivatives to alter membrane biophysical properties and modulate the activity of membrane-associated signaling proteins (PNAS, 2007; Laminar Pharmaceuticals, 2024).